menu
    • menu
    [{"orgOrder":0,"company":"Elevara Medicines","sponsor":"Forbion | Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"ELV001","moa":"CDK4\/6","graph1":"Immunology","graph2":"Phase I","graph3":"Elevara Medicines","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Elevara Medicines \/ Forbion | Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Elevara Medicines \/ Forbion | Sofinnova Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Elevara Medicines

    Menu

    Elevara Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elevara Medicines

                            United Kingdom arrow
                            BOS Manchester
                            Not Confirmed

                            Elevara Medicines

                            United Kingdom arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELV001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Forbion | Sofinnova Partners

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Elevara Medicines Raises $70M Series A to Advance Rheumatoid Arthritis Trial

                            Details : Series A financing for ELV001, a small molecule product targeting CDK4/6, to advance treatment for Rheumatoid Arthritis.

                            Product Name : TCK-276

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 22, 2025

                            Lead Product(s) : ELV001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Forbion | Sofinnova Partners

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth